Eaton Scientific Systems, Ltd. Advisor Jennifer R. Berman, MD to be Featured Guest on CBS Daytime Women's Talk Show "The Talk." The Segment is Scheduled to be Filmed Wednesday, September 26, 2012
"Once again, Dr. Berman is a featured expert guest on one of the country's most popular daytime talk shows for women," stated Michael Borkowski, CEO of Eaton Scientific. "Dr. Berman's presence on national network television alongside some the most recognizable women in all of entertainment will continue to draw attention to her role as scientific advisor and advocate of Tropine 3, Eaton's novel non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes."
The Talk is a TV talk show created by actress Sara Gilbert, also known for her role as Darlene Conner on the ABC sitcom Roseanne and for her recurring role as Leslie Winkle on CBS's hugely popular, The Big Bang Theory. The show first premiered on October 18, 2010, and airs on CBS as a part of CBS Daytime. Along with Gilbert, the sometimes controversial show features Julie Chen as moderator with Aisha Tyler, Sharon Osbourne, and Sheryl Underwood discussing the day's latest headlines while usually tying in the show's theme of motherhood or at least parenthood, such as by giving their opinions "through the eyes of mothers." It also contains celebrity interviews and segments for mothers and/or parents in general. Ratings for The Talk measured at the end of Season Two increased significantly compared to the end of Season 1; up +21% in households, +24% in viewers, +38% in women 25-54, and +33% in women 18-49. In March 2012, The Talk was renewed for a third season which officially started on September 10, 2012.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.
Forward-Looking Statements/Disclaimer
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.